Novartis plans to submit a supplementary new drug application with the FDA for Cosentyx in axial spondyloarthritis.
Cosentyx led to a decrease in disease activity for patients compared to patients who received a placebo in a Phase III trial. It also showed a sustained response and had a consistent safety profile at 52 weeks.
According to Novartis, there are roughly 1.7 million patients in the U.S. and European Union with axial spondyloarthritis.
More articles on devices:
How CTL Amedica has grown since the $10M acquisition in spine, and what lies ahead
Zimmer Biomet recalls legacy products & more: 10 device company notes
Sectra adds DePuy Synthes templates to preoperative planning solution — 3 details
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.